Some authors reported better usefulness in assessing interleukin-6 (IL-6) serum levels in differentiating PC patients from chronic or acute pancreatitis [7–9], or recently, leukemia inhibitory factor (LIF) was reported to be a promising serum biomarker of pancreatic malignancy [10]. Here, LIF is linked to acute pancreatitis.